0.645
0.01 (1.78%)
| Previous Close | 0.634 |
| Open | 0.640 |
| Volume | 340,665 |
| Avg. Volume (3M) | 930,837 |
| Market Cap | 31,298,722 |
| Price / Sales | 10.21 |
| Price / Book | 0.900 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -6,511.20% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 64.59% |
| Current Ratio (MRQ) | 8.10 |
| Operating Cash Flow (TTM) | -59.84 M |
| Levered Free Cash Flow (TTM) | -36.80 M |
| Return on Assets (TTM) | -32.66% |
| Return on Equity (TTM) | -82.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Werewolf Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -5.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.40 |
|
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.07% |
| % Held by Institutions | 62.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Asset Management Llc | 30 Sep 2025 | 4,309,860 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (B of A Securities, 985.61%) | Buy |
| Median | 5.50 (752.98%) | |
| Low | 4.00 (HC Wainwright & Co., 520.35%) | Buy |
| Average | 5.50 (752.98%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.801 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Dec 2025 | 4.00 (520.35%) | Buy | 0.687 |
| B of A Securities | 18 Nov 2025 | 7.00 (985.61%) | Buy | 0.915 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| EVNIN LUKE | - | 0.594 | -214,516 | -124,478 |
| Aggregate Net Quantity | -214,516 | |||
| Aggregate Net Value ($) | -124,478 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 0.594 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| EVNIN LUKE | Director | 15 Jan 2026 | Automatic sell (-) | 37,413 | 0.551 | 20,615 |
| EVNIN LUKE | Director | 14 Jan 2026 | Automatic sell (-) | 30,616 | 0.584 | 17,880 |
| EVNIN LUKE | Director | 13 Jan 2026 | Automatic sell (-) | 43,198 | 0.571 | 24,666 |
| EVNIN LUKE | Director | 12 Jan 2026 | Automatic sell (-) | 58,980 | 0.575 | 33,914 |
| EVNIN LUKE | Director | 09 Jan 2026 | Automatic sell (-) | 24,678 | 0.604 | 14,906 |
| EVNIN LUKE | Director | 08 Jan 2026 | Automatic sell (-) | 7,716 | 0.630 | 4,861 |
| EVNIN LUKE | Director | 07 Jan 2026 | Automatic sell (-) | 11,915 | 0.641 | 7,638 |
| Date | Type | Details |
|---|---|---|
| 18 Dec 2025 | Announcement | Werewolf Therapeutics Announces Pipeline and Business Updates |
| 07 Nov 2025 | Announcement | Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting |
| 04 Nov 2025 | Announcement | Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |